Trabectedin for Recurrent Grade II/III Meningioma

Summary

The aim of this study is to collect data on activity, toxicity and quality of life of trabectedin therapy in patients with recurrent high-grade meningioma.

Timeline

Start

2015-07

Primary completion

2017-07

Completion

2019-01-16

Outcome

Missed primary endpoint

registry analysis (superiority test); Local Standard of Care vs Trabectedin; p = 0.204; Hazard Ratio (HR) 1.42 (80% CI 0.997 to 2.028); Regression, Cox NCT02234050 ↗

Publications

• Hundsberger T, Surbeck W, Hader C, Putora PM, Conen K, Roelcke U. [Meningioma: management of the most common brain tumour]. Praxis (Bern 1994). 2016 Apr 13;105(8):445-51. doi: 10.1024/1661-8157/a002320. German.

Drugs

Indications